| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
Department of Neurology, The Middlesex Hospital, London, UK.
Thirty-five patients with early mild Parkinson's disease were treated from the outset with small doses of L-dopa (mean dose, 396 to 454 mg daily) and a peripheral decarboxylase inhibitor, for a mean of 6 years. Overall mortality ratio was 1.2:1, worse for women than for men. After 6 years of treatment, only one-third of patients were better, and drug-related complications were common (peak-dose dyskinesias in 54% of patients, off-period dystonia 20%, wearing-off effects 52%, on-off oscillations 6%, visual hallucinations and toxic confusional states 17%). We found no evidence that long-term results were markedly improved with low-dose regimens.
Address correspondence and reprint requests to Dr. Lees, Department of Neurology. The Middlesex Hospital, Mortimer Street, London, W 1, UK.
Accepted for publication March 5, 1986.
This article has been cited by other articles:
|
|
 |
|
  W. Cawello, M. Braun, and H. Boekens Absorption, Disposition, Metabolic Fate, and Elimination of the Dopamine Agonist Rotigotine in Man: Administration by Intravenous Infusion or Transdermal Delivery Drug Metab. Dispos., October 1, 2009; 37(10): 2055 - 2060. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. Lee, W.-M. Zhu, D. Stanic, D. I. Finkelstein, M. H. Horne, J. Henderson, A. J. Lawrence, L. O'Connor, D. Tomas, J. Drago, et al. Sprouting of dopamine terminals and altered dopamine release and uptake in Parkinsonian dyskinaesia Brain, June 1, 2008; 131(6): 1574 - 1587. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 W. Poewe The need for neuroprotective therapies in Parkinson's disease: A clinical perspective Neurology, May 23, 2006; 66(10_suppl_4): S2 - S9. [Abstract] [Full Text]
|
|
|
|
|
|
W. Poewe and F. Luessi Clinical studies with transdermal rotigotine in early Parkinson's disease Neurology, July 26, 2005; 65(2_suppl_1): S11 - S14. [Full Text]
|
|
|
|
|
|
P. Barone Clinical strategies to prevent and delay motor complications Neurology, September 23, 2003; 61(90063): S12 - 16. [Abstract] [Full Text]
|
|
|
|
|
|
J. Jankovic Levodopa strengths and weaknesses Neurology, February 1, 2002; 58(90001): S19 - 32. [Abstract] [Full Text]
|
|
|
|
|
|
W. C. Koller Treatment of early Parkinson's disease Neurology, February 1, 2002; 58(90001): S79 - 86. [Abstract] [Full Text]
|
|
|
|
|
|
C. W. Olanow, R. L. Watts, and W. C. Koller An algorithm (decision tree) for the management of Parkinson's disease (2001):: Treatment Neurology, June 12, 2001; 56(suppl_5): S1 - S88. [Full Text] [PDF]
|
|
|
|
|
|
A. Schrag and N. Quinn Dyskinesias and motor fluctuations in Parkinson's disease: A community-based study Brain, November 1, 2000; 123(11): 2297 - 2305. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. R. Bradley, M. J. Marino, M. Wittmann, S. T. Rouse, H. Awad, A. I. Levey, and P. J. Conn Activation of Group II Metabotropic Glutamate Receptors Inhibits Synaptic Excitation of the Substantia Nigra Pars Reticulata J. Neurosci., May 1, 2000; 20(9): 3085 - 3094. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Fahn Parkinson Disease, the Effect of Levodopa, and the ELLDOPA Trial Arch Neurol, May 1, 1999; 56(5): 529 - 535. [Full Text] [PDF]
|
|
|
|
 |
|
 A J Lees Comparison of therapeutic effects and mortality data of levodopa and levodopa combined with selegiline in patients with early, mild Parkinson's disease BMJ, December 16, 1995; 311(7020): 1602 - 1607. [Abstract] [Full Text]
|
|
|
|
|
|
C. H. Markham and S. G. Diamond Modification of Parkinson's Disease by Long-term Levodopa Treatment-Reply Arch Neurol, January 1, 1988; 45(1): 14 - 14. [Abstract] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
